Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

2018 ◽  
Vol 20 (8) ◽  
pp. 1937-1943 ◽  
Author(s):  
Emilie S. Andersen ◽  
Asger Lund ◽  
Jonatan I. Bagger ◽  
Camilla Andreasen ◽  
Magnus F. Grøndahl ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes

2017 ◽  
pp. E188-E199
Author(s):  
Abdulhalim Senyigit ◽  
Omur Tabak ◽  
Timur Orhanoglu ◽  
Aytac Karadag ◽  
Serdal Ugurlu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Microvascular Complications ◽  
Dipeptidyl Peptidase ◽  
Controlled Clinical Trial ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Purpose: Hyperglycemia is the major risk factor for microvascular complications in type 2 diabetes mellitus (T2DM) patients. This randomized controlled clinical trial aimed to investigate T2DM patients with microvascular complications with regard to possible relations among serum clusterin (CLU), amylin, secreted frizzled-related protein-4 (SFRP-4), glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) activities. Methods: Subject groups were defined as follows: T2DM without complications (n=25, F/M=9/16, age 53.9±11.1 years); T2DM+Retinopathy (n=25, F/M=13/12, age 63.8±7.1 years); T2DM+Nephropathy (n=25, F/M=13/12, age 58.7±14.4 years); T2DM+Neuropathy (n=25, F/M=15/10, age 63.2±9.6 years); and healthy control subjects (HC) (n=25). CLU, amylin, SFRP-4, DPP-4 and GLP-1 (total and active) activities were measured and compared in blood samples from type 2 diabetic patients with and without microvascular complications. Results: Significantly lower levels of DPP-4 and GLP-1total (P

Therapeutic Targets Underlying the Evolution of Potential Anti-Diabetic Agents: A Comprehensive Review

2021 ◽  
Vol 18 ◽  
Author(s):  
Siddhita Tiwari ◽  
Paranjeet Kaur ◽  
Deepali Gupta ◽  
Saumik Chaudhury ◽  
Manish Chaudhary ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Beta Cell ◽  
Glucose Level ◽  
Glycogen Phosphorylase ◽  
Dipeptidyl Peptidase ◽  
The Body ◽  
Dipeptidyl Peptidase 4 ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

: Type 2 Diabetes is termed as a chronic metabolic syndrome that occurs due to hyperglycaemia. Type 2 diabetes is growing worldwide really fast. Looking at all the circumstances, it was recognized that insulin check and Beta-cell brokenness are essential issues that are responsible for the unforeseen development of diabetes. Drugs for diabetes were found to have glucose level lessening impacts in the body and they were named as Glucagon-like peptide 1, amylin. Amylin is one of the hormones that show its action after having a meal; they have correlated activity to the pancreatic hormones. GLP-1 speedily corrupts via dipeptidyl-peptidase-4 in-vivo that leads to a decline in the said feasibility. Some other efficacious biological medicines that are being used for Type-2 Diabetes are 11beta-HSD-1 inhibitors or rivals in relation to glucocorticoids receptor, some other for reducing hepatic glucose level these are rival of glucagon receptor or maybe inhibitors to glycogen phosphorylase or fructose-1,6-biphosphatase, last but not least mounting urinary discarding of superfluity glucose those are SGLT inhibitors. Moreover, treatments related to Incretin can be glucagon-like peptide-1 [GLP-1] inhibitors and dipeptidyl peptidase 4 [DPP-4] inhibitors. Certain Non-incretin beta-cell stimulants are also in the phase of developments and they are glucokinase activators, G-protein-coupled receptors. These are soothing, antagonistic towards the oxidizing agent. Targets that cause glucose stimulant effect were glucose-6-phosphatase, glycogen phosphorylase and inhibition of same causes vice-versa. Some more novel targets are yet to be found; these superiors will additionally target metabolic ailment, as talking about the present situation it is one novel and primary clinical ailment that individual in the world estimated to suffer from the threat of 2nd type of diabetes.

scholarly journals Study the effect of Dipeptidyl Peptidase 4 Inhibitors as an Antidiabetic in Type 2 Diabetes Mellitus (T2DM)

2021 ◽  
Vol 11 (5) ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dpp Iv ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Dipeptidyl peptidase IV is a key regulator of insulin- stimulating hormones, glucagon-like peptide and glucose dependent insulinotrophic polypeptide. Thus it is a promising target for treatment of type 2 Diabetes mellitus. Inhibition of plasma Dipeptidyl peptidase IV enzyme lead to enhanced endogenous glucagon like peptide-1, GIP activity which ultimately results in the potentiating of insulin secretion by pancreatic cell and subsequent lowering blood glucose level, HbA [1c], glucose secretion, liver glucose production. One of the principal goals of diabetes management is to attain haemoglobin HbA [1c] treatment goals and prevent the onset or decrease the rate of occurrence of Microvascular conditions.2, 6 numerous treatment options are available for management of Type 2 Diabetes mellitus, various class of DPP IV inhibitor being explored such as Sitagliptin and Vildagliptin successfully launched. Several other novel DPP IV inhibitors are in pipeline, Unless there are clear contraindications, metformin monotherapy is prescribed, and if HbA [1c] targets are not attained after 3 months, 1 of several classes of agents could be added, such as sulfonylurea’s, Thiazolidinediones, dipeptidyl peptidase-4 inhibitors, - glucagon like peptide-1 receptor agonists, or basal insulin.2,6 Despite the broad range of therapeutic options, the attainment of HbA [1c] goals among patients with diabetes remains challenging, with just slightly more than half (52%) of diabetes patients attaining the common HbA [1c] goal of < 7.0%. The present review summarizes latest preclinical and clinical trial data of different DPP IV inhibitors with a special emphasis on their DPP8/9 fold selectivity and therapeutic advantages over GLP-1 based approach. Keywords: Diabetes 2, Dipeptidyl Peptidase-4, glucose-dependent insulinot

Comparison of amylase and lipase levels of patients with Type 2 diabetes under different treatment modalities

2021 ◽  
Author(s):  
Ramazan Cakmak ◽  
Ozge T Caklili ◽  
Sakin Tekin ◽  
Hulya Hacisahinogullari ◽  
Seher Tanrikulu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Basal Insulin ◽  
Dipeptidyl Peptidase ◽  
Treatment Modalities ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Insulin Secretagogues ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Aim: Study aims to assess amylase, lipase of patients with Type 2 diabetes under different types of treatments. Materials & methods: Patients’ treatment modalities including insulin, metformin, pioglitazone, sodium-glucose co-transporter-2 inhibitors, insulin secretagogues, dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists were compared. Results: There was no difference in amylase and lipase levels between dipeptidyl peptidase-4 inhibitor users and non-users (p = 0.2, p = 0.3, respectively) and glucagon like peptide-1 analog users and non-users (p = 0.1, p = 0.7, respectively). Patients who use insulin secretagogues had significantly higher amylase, lipase and (77.2 ± 39.8 vs 69.5 ± 33.0, p = 0,038 and 47.2 ± 33.2 vs 39.6 ± 26.8, p = 0.01, respectively) patients on basal insulin had lower amylase levels (69.9 ± 37.7 vs 77.2 ± 33.7, p = 0.014). Conclusion: Incretin-based therapies showed no difference in amylase and lipase levels whereas there was increase with secretagogues and decrease with basal insulin.

scholarly journals Vildagliptin in the Treatment of Type 2 Diabetes Mellitus

2013 ◽  
Vol 20 (2) ◽  
pp. 165-176
Author(s):  
Ariel Florenţiu ◽  
Radu Lichiardopol
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Important Place ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Type 2 Diabetes Treatment ◽  
Glucagon Like Peptide 1 ◽  
Current Guidelines

Abstract Novel therapeutic approaches are continuously being researched in type 2 diabetes. The incretin class of anti-diabetic agents, consisting of glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors, has already found an important place in the current guidelines. Vildagliptin is a potent dipeptidyl peptidase-4 inhibitor, with numerous trials in type 2 diabetes treatment, both in monotherapy and in combination therapy. This review focuses on vildagliptin pharmacological properties, clinical efficacy and safety, and pharmacoeconomic data.

Sign in / Sign up

Export Citation Format

Share Document